The current in vivo research aimed to study the efficacy of intranasal treatment of aged APP/PS1 mice with low-dose THC for slowing down cognitive function decline, lowering Aβ levels in the brain, inhibiting p-tau production, and improving mitochondrial function and overall AD attenuation. This evidence concerns the gene APP and Alzheimer disease.